ライフサイエンスコーパス: parathyroid

1 tterning and organogenesis of the thymus and parathyroids.

2 basis of oxyphil cell transformation in the parathyroids.

3 ntiation and morphogenesis of the thymus and parathyroids.

4 (COX)-positive and COX-negative areas of 19 parathyroids.

5 Parathyroid 4-dimensional computed tomographic scans (4D

6 Five lesions were interpreted incorrectly as parathyroid adenoma (false-positive), and all lesions ha

7 tiate between healthy parathyroid tissue and parathyroid adenoma from 18 patients.

8 al activity, and relative abundance of these parathyroid adenoma subpopulations likely reflect distin

9 Moreover, the parathyroid adenoma subtypes (chief cells and oxyphil ce

10 (CDKN2A, CDKN2B and RASSF1A) was analysed in parathyroid adenoma tissues (n = 30).

11 Parathyroid adenomas (PAs) causing primary hyperparathyr

12 Parathyroid adenomas and hyperplasia can be grouped into

13 14 in 94 patients with pathologically proven parathyroid adenomas or hyperplasia.

14 ectin-3 expression, consistent with atypical parathyroid adenomas, from 9 months of age.

15 1, a G1-S phase regulator, is upregulated in parathyroid adenomas.

16 tion-mediated inactivation of these genes in parathyroid adenomas.

17 lation of CCND1 regulatory genes in sporadic parathyroid adenomas.

18 here is little additional risk involved with parathyroid allotransplantation.

19 docrine tumours (P-NETs) in association with parathyroid and pituitary tumours.

20 h sensitivity-the unambiguous distinction of parathyroid and thyroid glands simultaneously in the con

21 gery: the identification and preservation of parathyroid and thyroid glands.

22 , and the associations for myeloid leukemia, parathyroid, and unknown primary tumors are, to our know

23 roles in biology but their functions in the parathyroid are unexplored.

24 None of the TPTX patients required delayed parathyroid AT to treat permanent hypoparathyroidism.

25 Preoperative parathyroid biopsy should be avoided.

26 Therefore, stimulation of the parathyroid by both hypocalcemia and uremia is dependent

27 and hyperplastic glands, and also in normal parathyroid by in situ hybridization, qRT-PCR, and immun

28 Nonlocalized patients had smaller parathyroids by size (1.2 vs 1.6 cm, P < 0.001) and mass

29 mice responded normally to activation of the parathyroid calcium-sensing receptor (Casr) by both hype

30 ial pHPT, reoperative parathyroidectomy, and parathyroid carcinoma are challenging entities that requ

31 ocalization are equivalent in the respective parathyroid cell populations.

32 Uremic rpS6(p-/-) mice had no increase in parathyroid cell proliferation compared with a marked in

33 mice with no increase in PTH mRNA levels and parathyroid cell proliferation compared with the 2- to 3

34 omplex 1 by rapamycin decreased or prevented parathyroid cell proliferation in secondary hyperparathy

35 e molecular pathways mediating the increased parathyroid cell proliferation remain undefined.

36 te that mTORC1 is a significant regulator of parathyroid cell proliferation through rpS6.

37 ed serum parathyroid hormone (PTH) level and parathyroid cell proliferation.

38 This activation correlated with increased parathyroid cell proliferation.

39 n modulate CaR responsiveness in HEK-293 and parathyroid cells independently of extracellular histidi

40 uppressed PTH secretion from perifused human parathyroid cells, and acidosis transiently increased PT

41 In both CaR-HEK and isolated bovine parathyroid cells, decreasing pHo from 7.4 to 7.2 rapidl

42 d active exogenous leptin uptake in cultured parathyroid cells.

43 The parathyroid chief and oxyphil cells produce parathyroid

44 n were detected in an overlapping fashion in parathyroid chief cells in adenoma and hyperplastic glan

45 sc confocal microscopy, electron microscopy, parathyroid culture, whole organ explant, and animal mod

46 rats and decreased levels of secreted PTH in parathyroid cultures.

47 The thymus and parathyroids develop from third pharyngeal pouch (3rd pp

48 ms that specify fate and regulate thymus and parathyroid development are not fully delineated.

49 encoding a transcription factor required for parathyroid development.

50 he parathyroid-fated domain and required for parathyroid development.

51 was required in a cell-autonomous manner for parathyroid differentiation.

52 was insufficient to expand the GCM2-positive parathyroid domain, indicating that multiple inputs, som

53 Management of the parathyroids during thyroidectomy is controversial.

54 termine the incidence of renal, thyroid, and parathyroid dysfunction associated with lithium use.

55 tigated the incidence of renal, thyroid, and parathyroid dysfunction in patients (aged >/=18 years) w

56 ed parathyroidectomy (FPTX) and open 4-gland parathyroid exploration (OPTX) for primary hyperparathyr

57 dependent of SHH signaling, are required for parathyroid fate specification.

58 m2, a transcription factor restricted to the parathyroid-fated domain and required for parathyroid de

59 Parathyroids from uremic and normal rats segregated on t

60 ances may affect the CaR-mediated control of parathyroid function and calcium metabolism in vivo.

61 eed baseline measures of renal, thyroid, and parathyroid function and regular long-term monitoring.

62 arathyroidism indicates their importance for parathyroid function and the development of hyperparathy

63 Obtaining a parathyroid gland and a kidney from the same donor reduc

64 showed that this technique is able to detect parathyroid gland devascularization before it is visuall

65 not reverse the arrest in tooth, thymus, and parathyroid gland development, suggesting that the relat

66 arathyroidism can be cured by removal of the parathyroid gland or glands but identification of patien

67 rogenital tract, pancreas, liver, brain, and parathyroid gland.

68 The parathyroid glands acting through PTH play a critical ro

69 ptin is a functionally active product of the parathyroid glands and stimulates PTH release.

70 ry conservation of abundant miRNAs in normal parathyroid glands and the regulation of these miRNAs in

71 The thymus and parathyroid glands arise from a shared endodermal primor

72 scularized (n = 32) and compromised (n = 27) parathyroid glands during thyroid surgery with an accura

73 We profiled microRNA (miRNA) in parathyroid glands from experimental hyperparathyroidism

74 rathyroidism rats and in vitro in uremic rat parathyroid glands in organ culture.

75 e thyroidectomies attempting to preserve the parathyroid glands in situ with an intact vascular pedic

76 on, with rates >fourfold higher than that in parathyroid glands of wild-type littermates (P<0.0001).

77 receptor were present in normal and diseased parathyroid glands, and if so, whether they had any func

78 n vertebrate-specific tissues, placenta, and parathyroid glands, begging questions on the evolutionar

79 emic level causes promiscuous effects in the parathyroid glands, kidneys, and other tissues, and the

80 cytometric analysis of resected adenomatous parathyroid glands, we have isolated and characterized c

81 dental disruption of blood supply to healthy parathyroid glands, which are responsible for regulating

82 d hypercalcemia and caused by hypersecreting parathyroid glands.

83 splantation, persistent hyperparathyroidism (parathyroid hormone > 130 ng/L) and bone turnover marker

84 s with secondary hyperparathyroidism (intact parathyroid hormone >/=300 pg/mL).

85 Compared with parathyroid hormone <33 pg/ml, parathyroid hormone >/=65 pg/ml was associated with a si

86 Compared with parathyroid hormone <33 pg/ml, parathyroid hormone >/=65

87 ge mean+/-SD single-pass renal extraction of parathyroid hormone (44.2%+/-10.3%) that exceeded the ex

88 Intermittent Parathyroid Hormone (I-PTH) is the only FDA approved ana

89 ients with hypercalcemia and elevated intact parathyroid hormone (iPTH) concentration were eligible i

90 citol treatment significantly reduced intact parathyroid hormone (P<0.001) and alkaline phosphatase (

91 um metabolism was defined as elevated intact parathyroid hormone (PTH) (>62 pg/mL) accompanied by a v

92 Parathyroid hormone (PTH) activates receptors on osteocy

93 cium through processes that are regulated by parathyroid hormone (PTH) and 1alpha,25-dihydroxyvitamin

94 Parathyroid hormone (PTH) and calcium levels, recurrent

95 Parathyroid hormone (PTH) and FGF23 are the primary horm

96 echanisms through which Pi intake stimulates parathyroid hormone (PTH) and fibroblast growth factor-2

97 Parathyroid hormone (PTH) and the sympathetic tone promo

98 The bone catabolic actions of parathyroid hormone (PTH) are seen in patients with hype

99 Continuous parathyroid hormone (PTH) blocks its own osteogenic acti

100 Previously, we have shown that intermittent parathyroid hormone (PTH) bone anabolic therapy involves

101 3 patients receiving hemodialysis with serum parathyroid hormone (PTH) concentrations higher than 500

102 ravenous calcimimetic etelcalcetide on serum parathyroid hormone (PTH) concentrations in patients rec

103 dc73(+/-) mice also had increased mean serum parathyroid hormone (PTH) concentrations.

104 ], 1,25-dihydroxyvitamin D [1,25(OH)2D], and parathyroid hormone (PTH) in maternal circulation and co

105 he PT-Dicer(-/-) mice did not increase serum parathyroid hormone (PTH) in response to acute hypocalce

106 Parathyroid hormone (PTH) induces osteoclast formation a

107 Genes related to the parathyroid hormone (PTH) influence cutaneous immune def

108 Parathyroid hormone (PTH) is a primary calcium regulator

109 Parathyroid hormone (PTH) is an important regulator of o

110 Parathyroid hormone (PTH) is recognized to be an importa

111 Parathyroid hormone (PTH) is the only current anabolic t

112 yroidism is characterized by increased serum parathyroid hormone (PTH) level and parathyroid cell pro

113 ce and impact of HPT, defined as an elevated parathyroid hormone (PTH) level, after renal transplanta

114 ibited reduced serum inorganic phosphate and parathyroid hormone (PTH) levels and decreased bone form

115 nvestigated the association between baseline parathyroid hormone (PTH) levels and major cardiovascula

116 l quantitative computed tomography (HRpQCT), parathyroid hormone (PTH) levels, and bone turnover mark

117 ned assessment of 25-OH-D with its regulator parathyroid hormone (PTH) may be required for optimal ev

118 ia, anti-KRN23 antibodies, or elevated serum parathyroid hormone (PTH) or creatinine.

119 Parathyroid hormone (PTH) orchestrates the signaling of

120 Intermittent administration of parathyroid hormone (PTH) promotes new bone formation in

121 alloproteinase-13 (MMP-13) transcription and parathyroid hormone (PTH) regulates HDAC4 to control MMP

122 aR) modulates renal calcium reabsorption and parathyroid hormone (PTH) secretion and is involved in t

123 ition of the abundant let-7 family increased parathyroid hormone (PTH) secretion in normal and uremic

124 , whether they had any functional effects on parathyroid hormone (PTH) secretion in parathyroid neopl

125 Upon parathyroid hormone (PTH) stimulation, the PTHR internal

126 A complex feedback mechanism between parathyroid hormone (PTH), 1,25(OH)2D3 (1,25D), and fibr

127 was the primary outcome, and serum calcium, parathyroid hormone (PTH), 1,25-dihydroxyvitamin D [1,25

128 ogenesis, confluent BMSCs were cultured with parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3 (1,2

129 In response to parathyroid hormone (PTH), a bone anabolic hormone, LepR

130 Human parathyroid hormone (PTH), a member of class B GPCRs, bi

131 parathyroid chief and oxyphil cells produce parathyroid hormone (PTH), express the calcium-sensing r

132 ercalcemic patients underwent measurement of parathyroid hormone (PTH), had documentation of hypercal

133 Teriparatide, a recombinant form of parathyroid hormone (PTH), is the only approved treatmen

134 transferrin saturation (TSAT) concentration, parathyroid hormone (PTH), IV vitamin D dose, cinacalcet

135 ata defined by their pretransplant levels of parathyroid hormone (PTH), low PTH (>65 to </=300 pg/mL;

136 ALN, parathyroid hormone (PTH), or saline (vehicle control) w

137 over and pronounced osteoblast resistance to parathyroid hormone (PTH), which is indicated by decreas

138 al to Cyp27b1 that mediates unique basal and parathyroid hormone (PTH)-, fibroblast growth factor 23

139 nique role of osteal macrophages in bone and parathyroid hormone (PTH)-dependent bone anabolism using

140 m baseline in blood and urine markers of the parathyroid hormone (PTH)-vitamin D-fibroblast growth fa

141 ostasis and is tightly regulated through the parathyroid hormone (PTH)/PTHrP receptor (PTH1R) signali

142 We reveal the existence of an ancient parathyroid hormone (Pth)4 in zebrafish that was seconda

143 Parathyroid hormone (PTH, 84 residues) and PTH-related p

144 ndomized to receive 20 mug recombinant human parathyroid hormone (teriparatide) or placebo for 18 mon

145 The parathyroid hormone 1 receptor (PTHR) is central to the

146 In another study, we showed that parathyroid hormone 1-34 and anti-sclerostin antibody at

147 Studies by Sato et al. reveal a role for parathyroid hormone 2 receptor (PTH2R) in extracellular

148 f 39 residues (TIP39), via its receptor, the parathyroid hormone 2 receptor (PTH2R), modulates fear m

149 Small interfering RNA-mediated silencing of parathyroid hormone 2 receptor (PTH2R), the receptor for

150 Synthetic parathyroid hormone [PTH(1-34)] has been investigated fo

151 Parathyroid hormone above the upper limit of normal (65

152 signature of the arrestin pathway-selective parathyroid hormone analog [d-Trp(12), Tyr(34)]bovine PT

153 splant patients significantly reduced intact parathyroid hormone and increased fibroblast growth fact

154 Paricalcitol decreases intact parathyroid hormone and the frequency of secondary hyper

155 alphas also inhibited internalization of the parathyroid hormone and type 2 vasopressin receptors.

156 terminal propeptide (PINP), osteocalcin, and parathyroid hormone as well as a transient decrease in t

157 substantial single-pass renal extraction of parathyroid hormone at a rate that exceeds glomerular fi

158 hly expressed in osteocytes, is regulated by parathyroid hormone both in vitro and in vivo, and prote

159 whether lower 25-hydroxyvitamin D and higher parathyroid hormone concentrations are associated with i

160 Higher serum parathyroid hormone concentrations showed a significant,

161 The proportionate renal extraction of parathyroid hormone correlated with eGFR.

162 operative success, defined by intraoperative parathyroid hormone criteria, and complication rates wer

163 Intact parathyroid hormone decreased in paricalcitol-treated pa

164 a common endocrine disease characterized by parathyroid hormone excess and hypercalcemia and caused

165 The endocrine and bone anabolic agent parathyroid hormone increased specialized proresolving m

166 ium concentration is within normal range but parathyroid hormone is elevated in the absence of any ob

167 x, and creatinine clearance, but with intact parathyroid hormone less than 100 pg/mL, were included a

168 ltiply by 0.25; P = .15), preoperative serum parathyroid hormone level (mean [SD], 114.5 [56.8] vs 13

169 rogression were age, baseline total or whole parathyroid hormone level greater than nine times the no

170 Regarding modifiable factors, higher average parathyroid hormone level was associated with greater ri

171 walking, and higher average log-transformed parathyroid hormone level were independently associated

172 ent risk was attenuated after adjustment for parathyroid hormone level, suggesting that parathyroid h

173 sphatemia and hypomagnesemia with low plasma parathyroid hormone level.

174 Patients on HD with intact parathyroid hormone levels </=300 pg/ml receiving dialys

175 nover in patients on HD with baseline intact parathyroid hormone levels </=300 pg/ml.

176 ficiency at day 7 having significantly lower parathyroid hormone levels (p<0.01).

177 lerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral me

178 itamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients w

179 6-month paricalcitol supplementation reduced parathyroid hormone levels and proteinuria, attenuated b

180 Parathyroid hormone levels decreased over the study peri

181 s induced by aldosteronism in which elevated parathyroid hormone levels raise the risk of adverse car

182 baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on par

183 Median intact parathyroid hormone levels were lower and severe hyperpa

184 mice had significantly lower serum FGF23 and parathyroid hormone levels, and higher renal 1-alpha-hyd

185 response or a hormonal response to decreased parathyroid hormone levels, we subjected osteocytes to a

186 ents also displayed higher plasma FGF-23 and parathyroid hormone levels.

187 In this study, we report that TIP39, a parathyroid hormone ligand family member that was recent

188 Pth4, an ancient parathyroid hormone lost in eutherian mammals, reveals a

189 Impaired renal clearance of parathyroid hormone may contribute to secondary hyperpar

190 r parathyroid hormone level, suggesting that parathyroid hormone may mediate this association.

191 y invasive parathyroidectomy, intraoperative parathyroid hormone monitoring via a reliable protocol i

192 strogen deficiency and sustained exposure to parathyroid hormone or RANKL.

193 The G protein-coupled parathyroid hormone receptor (PTHR) regulates mineral-io

194 The parathyroid hormone receptor 1 (PTHR1) is a member of th

195 Using an agonist of parathyroid hormone receptor-1 (PTHR1), a G protein-coup

196 tain interacting partners such as Lfc or the parathyroid hormone receptor.

197 een the groups, patients who did not mount a parathyroid hormone response to vitamin D deficiency had

198 nthracenyl-terpyridine as a modulator of the parathyroid hormone response.

199 ositively by 1,25(OH)2D3, retinoic acid, and parathyroid hormone through both intergenic and intronic

200 xyvitamin D was 26.3 +/- 11.2 ng/ml and mean parathyroid hormone was 41.2 +/- 17.3 pg/ml.

201 Serum 25-hydroxyvitamin D and intact parathyroid hormone were measured from previously frozen

202 Normal serum phosphate and parathyroid hormone were observed in HMWKO mice.

203 actor 23 was, on average, lower than that of parathyroid hormone with greater variability across indi

204 racteristics, dietary intakes, fasting serum parathyroid hormone, 25-hydroxyvitamin D [25(OH)D], and

205 ulated by numerous factors, including BMP-2, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D3 (

206 ium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone, and 24,25-dihydroxyvitamin D did no

207 use of monoclonal or polyclonal antibodies), parathyroid hormone, and albumin.

208 ong hormones, including 1,25(OH)2D3 (1,25D), parathyroid hormone, and fibroblast growth factor 23 (FG

209 ar, serum osteocalcin, total calcium, intact parathyroid hormone, and increased serum C telopeptide.

210 plasma levels of FGF23, calcium, phosphate, parathyroid hormone, and vitamin D metabolites.

211 FGF23, despite having high concentrations of parathyroid hormone, but administration of exogenous 1,2

212 evels, serum calcium homeostasis biomarkers (parathyroid hormone, calcium, and 25-hydroxyvitamin D),

213 etermined the single-pass renal clearance of parathyroid hormone, fibroblast growth factor 23, vitami

214 ccurred in serum calcium, phosphorus, intact parathyroid hormone, or C-reactive protein levels, cinac

215 not be explained by hypocalcemia, changes in parathyroid hormone, or fibroblast growth factor 23.

216 etabolic pathway (e.g., 25-hydroxyvitamin D, parathyroid hormone, phosphorus) had little impact.

217 nine, free thyroxine, free triiodothyronine, parathyroid hormone, prolactin, N-terminal pro-brain nat

218 as phosphates, fibroblast growth factor 23, parathyroid hormone, sclerostin, or vitamin D and their

219 ffect on basal bone resorption, it inhibited parathyroid hormone- and ovariectomy-induced OC activati

220 der these circumstances both agents enhanced parathyroid hormone-induced osteoblast differentiation a

221 5 (Gdf5), the transcription factor Erg, and parathyroid hormone-like hormone (Pthlh), and selection

222 , and Ihh target genes Patched 1 (Ptch1) and parathyroid hormone-like peptide (Pthlh) were down-regul

223 The majority of cells expressing parathyroid hormone-related peptide (PTHrP) are in the d

224 Parathyroid hormone-related peptide (PTHrP) is recognize

225 pression in chondrocytes strictly depends on parathyroid hormone-related peptide (PTHrP) signaling pa

226 r translocation of Gli2 and transcription of parathyroid hormone-related peptide (PTHrP), a key regul

227 st and prostate cancer metastasis biomarker, parathyroid hormone-related peptide (PTHrP).

228 ATDC5 chondrogenic cells is downregulated by parathyroid hormone-related peptide through transcriptio

229 ix protein 1, a direct targeting molecule of parathyroid hormone-related peptide, negatively regulate

230 Parathyroid hormone-related protein (PTHrP) contributes

231 K14-PTHrP transgenic mice [which overexpress parathyroid hormone-related protein (PTHrP) in their dev

232 Parathyroid hormone-related protein (PTHrP) is a critica

233 Parathyroid hormone-related protein (PTHrP) is produced

234 Increased levels of parathyroid hormone-related protein (PTHrP), known to in

235 egulates endochondral ossification in both a parathyroid hormone-related protein (PTHrP)-dependent an

236 as been made in determining the roles of the parathyroid hormone-related protein, Indian hedgehog, fi

237 or the quantification of a cancer biomarker (parathyroid hormone-related protein, PTHrP) in a real cl

238 sis in the absence of the receptor (PPR) for parathyroid hormone-related protein.

239 ts increase is associated with a decrease in parathyroid hormone.

240 (receptor activator of NFkappaB ligand) and parathyroid hormone.

241 er characterized by autonomous production of parathyroid hormone.

242 or inappropriately normal concentrations of parathyroid hormone.

243 er levels of serum calcium, phosphorous, and parathyroid hormone; and nutritional vitamin D, cinacalc

244 cancer cachexia, we show that tumour-derived parathyroid-hormone-related protein (PTHrP) has an impor

245 Parathyroid-hormone-type 1 receptor (PTH1R) is extensive

246 Of the 100 consecutive patients with parathyroid hyperplasia, 29 received conventional treatm

247 en the standard of care for the treatment of parathyroid hyperplasia.

248 However, preservation of the parathyroids in situ during preventive thyroidectomy com

249 ion, whereas others recommend preserving the parathyroids in situ.

250 id nodule (OR, 1.82; 95% CI, 1.01-3.28), and parathyroid lesion in the inferior position (OR, 6.82; 9

251 CTs and intraoperative findings, followed by parathyroid lesion in the inferior position and parathyr

252 Parathyroid lesion size of 10 mm or less (odds ratio [OR

253 athyroid lesion in the inferior position and parathyroid lesion size of 10 mm or less.

254 characterize factors associated with missed parathyroid lesions on preoperative 4D-CTs and to invest

255 Ninety-four patients had 110 parathyroid lesions, including 11 patients with multigla

256 dings in the number and location of abnormal parathyroid lesions.

257 t but not overwhelming evidence for thyroid, parathyroid, lung, and unknown primary tumors, meningiom

258 Expression of the parathyroid marker Gcm2 was initiated but was quickly do

259 Dicer1 knockout (PT-Dicer(-/-) ) mice where parathyroid miRNA maturation is blocked.

260 We identified parathyroid miRNAs that were dysregulated in experimenta

261 ts on parathyroid hormone (PTH) secretion in parathyroid neoplasms.

262 e yet considerably limited in complexity (no parathyroids, no skin).

263 d that the mTOR pathway was activated in the parathyroid of rats with secondary hyperparathyroidism i

264 In the past 10-year period, 1368 parathyroid operations for primary hyperparathyroidism w

265 normal and uremic rats, as well as in mouse parathyroid organ cultures.

266 ally distinct oxyphil and chief cells within parathyroid primary adenomas and provide evidence that p

267 activity of GCM2, suggesting that GCM2 is a parathyroid proto-oncogene.

268 recurrent or persistent hyperparathyroidism, parathyroid reoperations, morbidity, and mortality were

269 id transplantation may represent a permanent parathyroid replacement therapy.

270 rm a technetium 99m sestamibi ((99m)Tc MIBI) parathyroid scan.

271 Parathyroid scintigraphy plays a major role in defining

272 deep-sequencing showed that human and rodent parathyroids share similar profiles.

273 parathyroidectomy and autotransplantation of parathyroid slivers to the nondominant forearm or to the

274 ed conventional (Cdc73(+/-)) and conditional parathyroid-specific (Cdc73(+/L)/PTH-Cre and Cdc73(L/L)/

275 To study this, we generated parathyroid-specific Dicer1 knockout (PT-Dicer(-/-) ) mi

276 The modalities of parathyroid surgery have changed over the last 2 decades

277 ommendations for patients who do not undergo parathyroid surgery include monitoring of serum calcium

278 roidism who underwent triple-phase 4D CT and parathyroid surgery resulting in pathologically proved r

279 ding which patients should be considered for parathyroid surgery.

280 py was used to differentiate between healthy parathyroid tissue and parathyroid adenoma from 18 patie

281 athyroidism is due to a benign overgrowth of parathyroid tissue either as a single gland (80% of case

282 ed parathyroid tissue may be used to confirm parathyroid tissue intraoperatively.

283 Ex vivo aspiration of resected parathyroid tissue may be used to confirm parathyroid ti

284 Devascularized normal parathyroid tissue should be autotransplanted.

285 ilt to discriminate healthy from adenomatous parathyroid tissue was able to correctly classify all sa

286 0 mg of adenomatous or hyperplastic diseased parathyroid tissue was prepared and processed according

287 lation of these genes was observed in normal parathyroid tissue.

288 (p < 0.01) in adenomatous compared to normal parathyroid tissue.

289 miRNAs are essential for the response of the parathyroid to both acute and chronic hypocalcemia and u

290 Parathyroid transplantation may represent a permanent pa

291 Parathyroid tumor infiltrating lymphocytes are T cells b

292 lated cell cycle mechanism may contribute to parathyroid tumorigenesis.

293 Parathyroid tumour development, and elevations in serum

294 ies, which have established mouse models for parathyroid tumours and uterine neoplasms that develop i

295 Parathyroid tumours in Cdc73(+/-), Cdc73(+/L)/PTH-Cre an

296 nant disorder characterized by occurrence of parathyroid tumours, often atypical adenomas and carcino

297 TH-Cre and Cdc73(L/L)/PTH-Cre mice developed parathyroid tumours, which had nuclear pleomorphism, fib

298 dized uptake value (SUVmax) between abnormal parathyroid uptake and physiologic thyroid uptake.

299 ) alterations in the three cell types of the parathyroids using multiplex real-time PCR and next-gene

300 t Imaging (LSCI) for real-time assessment of parathyroid viability.

301 Individual parathyroids were autotransplanted only if they appeared